Antineoplastic Agents: Hormones and Antagonists
OARIM1 “Arimidex tablet” 1 mg/tab
適應症：治療停經後婦女晚期乳癌。其療效對於雌激素接受器陰性之病患尚未被證實，除非這些病患曾經對tamoxifen有陽性反應。輔助治療停經後婦女且荷爾蒙接受器為陽性的早期侵犯性乳癌。輔助治療已使用tamoxifen 2-3年之停經後婦女且荷爾蒙接受器為陽性的早期乳癌。
Usual dose:
Adjuvant treatment of early breast cancer: PO 1 mg qd.
1st-line treatment, locally advanced metastatic breast cancer: PO 1 mg qd.
Breast cancer with disease progression following tamoxifen: PO 1 mg qd.
Precaution:
Decreased bone mineral density, elevated LDL serum cholesterol, ischemic heart disease, increased risk of ischemic cardiovascular events.
Adverse effect:
Common: arthritis, arthralgia, bone pain, asthenia, back pain, pain, cough increased, dyspnea, pharyngitis, depression, headache, nausea, rash, vasodilatation, peripheral edema.
Serious: anaphylaxis, angioedema, urticaria, anemia, leukopenia, thromboembolism, thrombophlebitis, hypercholesterolemia, musculoskeletal events and fractures, vaginal hemorrhage.
健保使用規範：
1.停經後雌激素接受器為陽性或不清楚之局部晚期或轉移性乳癌第一線治療。(92/3/1)
2.停經後婦女晚期乳癌，雌激素接受器為陰性，但曾對tamoxifen有陽性反應者。(92/3/1)
3.停經後婦女罹患早期侵犯性乳癌，經外科手術切除後且雌激素接受器為陽性，且有血栓栓塞症或子宮內膜異常增生的高危險群，而無法使用tamoxifen治療者。(93/6/1)
備註：療程期間以不超過五年為原則。血栓栓塞症或子宮內膜異常增生的高危險群需符合下列情形之一：(1)有腦血管梗塞病史者；(2)有有靜脈血栓栓塞症病史者；(3)有子宮異常出血病史，且「經陰道超音波檢查」判定為子宮內膜異常增生的高危險群。